(Q35192415)

English

Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1 reference

Europe PubMed Central

Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

author name string

Jan Lehmann

1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Margitta Retz

2

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Michael Stöckle

3

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Critical Reviews in Oncology Hematology

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

47

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

171-179

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of patients with advanced cancer using the Karnofsky performance status

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality adjusted survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The Karnofsky Performance Status Scale re-examined: a cross-validation with the EORTC-C30

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment pathways, resource use and costs in the management of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of Medicare costs in elderly beneficiaries with breast, colorectal, lung, or prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine-containing regimens in bladder cancer: A new standard of care

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900080-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1040-8428(03)00080-5

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35192415&oldid=1606710731"